NDC 72205-200-11 - Roflumilast
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 72205-200
- Requested NDC
- 72205-200-11
- Package NDCs from labels
- 72205-200-30, 72205-200-90, 72205-200-11, 72205-200-06
- Manufacturer
- Novadoz Pharmaceuticals LLC | MSN LABORATORIES PRIVATE LIMITED | MSN Pharmaceuticals Inc.
- Effective date
- 2024-08-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Roflumilast | Novadoz Pharmaceuticals LLC | MSN LABORATORIES PRIVATE LIMITED | MSN Pharmaceuticals Inc. | 2024-08-27 | Human Prescription Drug Label |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 72205-200-06 | Roflumilast | 10 in 1 CARTON | TABLET | 10 | 3 | |
| 72205-200-11 | Roflumilast | 10 in 1 BLISTER PACK | TABLET | 10 | 3 | |
| 72205-200-30 | Roflumilast | 30 in 1 BOTTLE | TABLET | 30 | 3 | |
| 72205-200-90 | Roflumilast | 90 in 1 BOTTLE | TABLET | 90 | 3 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 72205-200-30 | EA - Each | 72205-200 | 015f9d85-d981-4de7-a9b5-16f96ad84dee | 1 | 2022-11-07 |
| 72205-200-90 | EA - Each | 72205-200 | d0e8287a-ca75-4fd4-a5e6-f29ea6bb6343 | 1 | 2022-11-07 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Roflumilast | ROFLUMILAST | Zydus Pharmaceuticals USA Inc. | 84145572-f320-4c3f-ab29-bd9f6c18746c | 2024-08-16 | Warnings, Adverse reactions | 2001319 1091839 0P6C6ZOP5U |
| ROFLUMILAST | ROFLUMILAST | Bryant Ranch Prepack | fa9c3bea-a04d-4ea9-ade9-ee8d9f6b1f72 | 2024-08-15 | Warnings, Adverse reactions | 1091839 0P6C6ZOP5U |
| Roflumilast | ROFLUMILAST | Zydus Lifesciences Limited | e87287bd-eae3-46c3-9072-04800aeabf40 | 2024-08-12 | 2001319 1091839 0P6C6ZOP5U | |
| Pure Cornstarch Baby | CORN STARCH | Walgreen Company | d0e9bd13-b568-4f7e-b036-8d23e71ad8bf | 2024-03-25 | Warnings | O8232NY3SJ |
| Roflumilast | ROFLUMILAST | Camber Pharmaceuticals, Inc. | f25a0230-3cf6-4366-bebe-0ea5ff8de5ab | 2023-04-28 | Warnings, Adverse reactions | 2001319 1091839 0P6C6ZOP5U |
| Refresh Digital PF | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | 97e83e68-6374-4df4-93f6-d707fc32748d | 2022-11-28 | Warnings | 6OZP39ZG8H |
| Refresh Digital | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | b2bd34d4-fab9-4f4b-9be2-5d30b55f5b81 | 2022-11-28 | Warnings | 6OZP39ZG8H |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | ebd0839e-2e1d-4e0e-986c-19f1f5c76358 | 2022-09-15 | Warnings | 6OZP39ZG8H |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, AND POLYSORBATE 80 | Allergan, Inc. | aaa943e4-7c38-4c5a-b7c0-5a656d8cafc0 | 2022-09-01 | Warnings | 6OZP39ZG8H |
| REFRESH Optive Mega-3 | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | c5f2b3f2-2071-45bd-a010-67f848bc0233 | 2022-06-30 | Warnings | 6OZP39ZG8H |
| ROFLUMILAST | ROFLUMILAST | Solco Healthcare US, LLC. | 4251c764-7224-4f94-9de7-b6c76cb1f5cd | 2022-05-10 | Warnings, Adverse reactions | 1091839 0P6C6ZOP5U |
| Daliresp | ROFLUMILAST | AstraZeneca Pharmaceuticals LP | c9a1d0a8-581f-4f91-a2b8-f419192d0ebf | 2020-03-12 | Warnings, Adverse reactions | 2001319 1091839 0P6C6ZOP5U |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.